Naratriptan for the treatment of acute migraine: Meta-analysis of randomised controlled trials

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 2, 2004, Pages 73-82

  Ashcroft, Darren M ^a   Millson, David ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Meta analyis; Migraine; Naratriptan

Indexed keywords

NAPROXEN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ACUTE DISEASE; ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HUMAN; INCIDENCE; LICENCE; MALAISE; META ANALYSIS; MIGRAINE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; THORAX PAIN; VOMITING;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; MIGRAINE DISORDERS; OXAZOLIDINONES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SUMATRIPTAN; TRIAZOLES; TRYPTAMINES;

EID: 1342347751     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.890     Document Type: Article

References (33)

1. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin 1997; 15(1): 1-13.
2. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999; 53(3): 537-542.
3. Dowson A, Jagger S. The UK migraine patient survey: quality of life and treatment. Curr Med Res Opin 1999; 15(4): 241-253.
4. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM 1996; 89(1): 77-84.
5. Hu XH, Markson LE, Lipton RB, Stewart WE, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159(8): 813-818.
6. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18(8): 532-538.
7. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38(3): 184-190.
8. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60(6): 1259-1287.
9. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001; 28(1): 30-41.
10. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358(9294): 1668-1675.
11. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision-making in migraine management. J Drug Assessment 2002; 5: 11-32.
12. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002; 97(3): 247-257.
13. Tfelt-Hansen P. How to define the best efficacy parameters for migraine. Cephalalgia 1997; 17: 6-8.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8(Suppl. 7): 1-96.
15. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31(5): 295-299.
16. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Br Med J 1994; 309(6964): 1286-1291.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188.
19. Fuseau E, Webster C, Asphamejad M, Huffman C. Factors affecting oral naratriptan pharmacokinetics in migraine subjects. J Neurol Sci 1997; 150: S33.
20. Klassen A, Elkind A, Asgharnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 1997; 37(10): 640-645.
21. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 1997; 49(6): 1485-1490.
22. Bates D, Winter P. Efficacy and tolerability of naratriptan tablets (0.1-2.5mg) in the acute treatment of migraine. Eur J Neurol 1998; 5: S48-S59.
23. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999; 42(3): 173-179.
24. Schoenen J, Jones M, Kane K, van Assche P, Saiers J. Naratriptan 2.5 mg tablets have a similar efficacy in the acute treatment of migraine as zolmitriptan 2.5 mg tablets, but exhibit a longer duration of action and are better tolerated: results of a comparator study. AAN Toronto 1999.
25. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. Clin Ther 2000; 22(8): 981-989.
26. Gobel H, Heinze A, Heinze-Kuhn K, Zumbroich V. Triptan plus NSAID with long half-life: increase of efficacy and reduction of headache recurrence in acute migraine. Copenhagen, Denmark 2000;
27. Havanka H, Dahlof C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000; 22(8): 970-980.
28. Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40(7): 513-520.
29. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346(4): 257-270.
30. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35(7): 387-396.
31. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39: S20-S26.
32. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42: 3-9.
33. Bateman DN. Triptans and migraine. Lancet 2000; 355(9207): 860-861.